ASH 2020 | Major ALL treatment updates at ASH 2020
Daniel DeAngelo
• 3 Dec 2020
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the major themes in the acute lymphoblastic leukemia (ALL) treatment landscape that are important moving forward. ASH 2020 will see presentations on the importance of measurable residual disease profiling for ALL and its ability to predict survival outcomes. Therapeutic advances will be discussed focusing on CAR-T cell developments, where there is lots of interest in reducing toxicity, prolonging responses, and targeting T-cell ALL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
